Table 3 Treatment terminations for adverse events in original and re-employed methotrexate therapies
| Â | Â | Re-employed course | Total | |
|---|---|---|---|---|
| Â | Â | No adverse event | Adverse event | Â |
Original Course | No adverse event | 45 (13.7 ± 5.2/18.4 ± 5.3) | 10 (10.5 ± 3.8/13.5 ± 4.4) | 55 (13.1 ± 5.1/17.5 ± 5.5) |
|  | Adverse event | 16 (10.2 ± 3.6/14.8 ± 6.3) | 8 (8.6 ± 1.3/9.1 ± 2.9) | 24 (9.7 ± 3.1/12.9 ± 6.2) |
Total | 61 (12.8 ± 5.0/17.5 ± 5.7) | 18 (9.7 ± 3.2/11.5 ± 4.4) | 79 (12.1 ± 4.8/16.1 ± 6.0) | |